---
title: "CEVIRA, a non-invasive therapy for cervical precancerous lesions, approved in China by Asieris Pharmaceuticals."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277602183.md"
description: "Photocure ASA, a leading player in bladder cancer treatment (OSE: PHO), has reported through its partner Asieris Pharmaceuticals (SSE: 688176) that APL-1702, known as CEVIRA®, has obtained the Drug Registration Certificate. This significant milestone was achieved as of March 3, 2026, marking a major advancement for the companies involved."
datetime: "2026-03-03T09:54:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277602183.md)
  - [en](https://longbridge.com/en/news/277602183.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277602183.md)
generator: "portal-rs"
---

# CEVIRA, a non-invasive therapy for cervical precancerous lesions, approved in China by Asieris Pharmaceuticals.

Photocure ASA, a leading player in bladder cancer treatment (OSE: PHO), has reported through its partner Asieris Pharmaceuticals (SSE: 688176) that APL-1702, known as CEVIRA®, has obtained the Drug Registration Certificate. This significant milestone was achieved as of March 3, 2026, marking a major advancement for the companies involved.

### Related Stocks

- [688176.CN](https://longbridge.com/en/quote/688176.CN.md)

## Related News & Research

- [Oncoinvent publishes corporate presentation on Radspherin alpha therapy for peritoneal metastases](https://longbridge.com/en/news/296475294.md)
- [Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing](https://longbridge.com/en/news/296318843.md)
- [20:00 ETAbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma](https://longbridge.com/en/news/296036085.md)
- [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md)
- [World’s First Solid-Tumor CAR-T Therapy Begins Rollout in China With First Foreign Patient](https://longbridge.com/en/news/296349187.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**